Lv65
2610 积分 2025-01-06 加入
A pragmatic, single-arm clinical trial of a dose modification algorithm for preventing cytopenia-related delays during FOLFOX chemotherapy
9天前
已关闭
Efficacy and safety of sparsentan versus irbesartan in patients with IgA nephropathy (PROTECT): 2-year results from a randomised, active-controlled, phase 3 trial
16天前
已完结
Safety, tolerability, and efficacy of alixorexton, a selective orexin 2 receptor agonist for narcolepsy type 1 (Vibrance-1): a randomised, double-blind, placebo-controlled, phase 2 trial
29天前
已完结
Sparsentan in patients with IgA nephropathy: a prespecified interim analysis from a randomised, double-blind, active-controlled clinical trial
1个月前
已完结
The outcome of IgAN: a time of reflection in the perspective of new opportunities
1个月前
已完结
Iptacopan in IgA Nephropathy — Final 24-Month Data
1个月前
已完结
Sibeprenlimab in IgA Nephropathy — Interim Analysis of a Phase 3 Trial
2个月前
已完结
Current Roles of Neoadjuvant and Perioperative Immunotherapy in Non–Small Cell Lung Cancer
2个月前
已完结
Trastuzumab Deruxtecan after Endocrine Therapy in Metastatic Breast Cancer
2个月前
已完结
Nefecon in IgA nephropathy: real-world renal efficacy, safety profile, and treatment response from a 9-month retrospective cohort analysis
2个月前
已完结
皖公网安备34019202002308
